Leonidaz Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.60 M
as on 19-12-2024
- Paid Up Capital ₹ 4.60 M
as on 19-12-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 M
as on 19-12-2024
- Revenue -15.21%
(FY 2020)
- Profit -65.21%
(FY 2020)
- Ebitda 4.89%
(FY 2020)
- Net Worth 375.07%
(FY 2020)
- Total Assets 27.05%
(FY 2020)
About Leonidaz Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.60 M and a paid-up capital of Rs 4.60 M.
The company currently has active open charges totaling ₹4.00 M.
Mechery Jayaprakash, Moosari Ramesh, and Mechery Chandran serve as directors at the Company.
- CIN/LLPIN
U24232KL2005PTC018671
- Company No.
018671
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Sep 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Malappuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Leonidaz Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mechery Jayaprakash  | Managing Director | 28-Sep-2005 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Moosari Ramesh | Director | 28-Sep-2005 | Current |
| Mechery Chandran | Director | 28-Sep-2005 | Current |
Financial Performance of Leonidaz Pharmaceuticals.
Leonidaz Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 15.21% decrease. The company also saw a substantial fall in profitability, with a 65.21% decrease in profit. The company's net worth Soared by an impressive increase of 375.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Leonidaz Pharmaceuticals?
In 2020, Leonidaz Pharmaceuticals had a promoter holding of 91.64% and a public holding of 8.36%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 10 Aug 2006 | ₹4.00 M | Open |
How Many Employees Work at Leonidaz Pharmaceuticals?
Leonidaz Pharmaceuticals has a workforce of 20 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Leonidaz Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Leonidaz Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
